155 related articles for article (PubMed ID: 15205948)
1. Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
Patel M; Agarwal R; Ardalan B
J Cancer Res Clin Oncol; 2004 Aug; 130(8):453-9. PubMed ID: 15205948
[TBL] [Abstract][Full Text] [Related]
2. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin.
Iigo M; Nishikata K; Hoshi A
Jpn J Cancer Res; 1992 Apr; 83(4):392-6. PubMed ID: 1387127
[TBL] [Abstract][Full Text] [Related]
4. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
[TBL] [Abstract][Full Text] [Related]
5. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
Miyaki Y; Suzuki K; Koizumi K; Kato T; Saito M; Kamiyama H; Maeda T; Shibata K; Shiya N; Konishi F
Int J Oncol; 2012 Jan; 40(1):217-26. PubMed ID: 21901246
[TBL] [Abstract][Full Text] [Related]
6. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Fischel JL; Rostagno P; Formento P; Dubreuil A; Etienne MC; Milano G
Br J Cancer; 2001 Feb; 84(4):579-85. PubMed ID: 11207057
[TBL] [Abstract][Full Text] [Related]
7. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
[TBL] [Abstract][Full Text] [Related]
8. Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway.
Granci V; Cai F; Lecumberri E; Clerc A; Dupertuis YM; Pichard C
Br J Nutr; 2013 Apr; 109(7):1188-95. PubMed ID: 22874769
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
Tanaka R; Ariyama H; Qin B; Shibata Y; Takii Y; Kusaba H; Baba E; Mitsugi K; Harada M; Nakano S
Oncol Rep; 2005 Sep; 14(3):683-8. PubMed ID: 16077975
[TBL] [Abstract][Full Text] [Related]
10. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
11. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
12. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
13. in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
Inoue Y; Tanaka K; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M
Int J Oncol; 2006 Feb; 28(2):479-86. PubMed ID: 16391804
[TBL] [Abstract][Full Text] [Related]
14. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.
Cao D; Russell RL; Zhang D; Leffert JJ; Pizzorno G
Cancer Res; 2002 Apr; 62(8):2313-7. PubMed ID: 11956089
[TBL] [Abstract][Full Text] [Related]
15. Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine.
Hector S; Tummala R; Kisiel ND; Diegelman P; Vujcic S; Clark K; Fakih M; Kramer DL; Porter CW; Pendyala L
Cancer Chemother Pharmacol; 2008 Aug; 62(3):517-27. PubMed ID: 17987291
[TBL] [Abstract][Full Text] [Related]
16. Irreversible cytotoxic effect of a novel lowly immunosuppressive antitumor fluorouridine derivative, UK-21.
Mori H; Nakayama K; Ishida R; Ito S; Nagai H; Koda A
Anticancer Drugs; 1997 Jun; 8(5):482-8. PubMed ID: 9215612
[TBL] [Abstract][Full Text] [Related]
17. [A case of metastatic colon cancer treated with oxaliplatin combination chemotherapy].
Tsujie M; Fujiwara S; Kida H; Hayashi N; Fukuchi S; Yoshida T; Ebisui C; Sakita I; Hasuike Y; Fujimoto T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1774-5. PubMed ID: 16315937
[TBL] [Abstract][Full Text] [Related]
18. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Arnould S; Guichard S; Hennebelle I; Cassar G; Bugat R; Canal P
Biochem Pharmacol; 2002 Oct; 64(8):1215-26. PubMed ID: 12234602
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
Inoue Y; Miki C; Watanabe H; Hiro J; Toiyama Y; Ojima E; Yanagi H; Kusunoki M
J Gastroenterol; 2006 Dec; 41(12):1149-57. PubMed ID: 17287894
[TBL] [Abstract][Full Text] [Related]
20. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Sharma RI; Smith TA
J Nucl Med; 2008 Aug; 49(8):1386-94. PubMed ID: 18632807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
